Skip to main content
Clinical Trials/NL-OMON56183
NL-OMON56183
Withdrawn
Not Applicable

A multi-center, non-randomized study to characterize biomarkers in cerebrospinal fluid (CSF) of patients with infantile-onset (IOPD) or late-onset Pompe disease (LOPD) - ASY17795

Sanofi BV0 sites3 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
acid alpha glucosidase deficiency
Sponsor
Sanofi BV
Enrollment
3
Status
Withdrawn
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
Sanofi BV

Eligibility Criteria

Inclusion Criteria

  • I 01\. Participants who have a confirmed diagnosis of LOPD and clinical signs or
  • symptoms OR
  • participants who have a confirmed diagnosis of IOPD.
  • I 02\. Capable of giving signed informed consent as described in Appendix 1
  • (Section 10\.1\) of
  • the protocol which includes compliance with the requirements and restrictions
  • listed in the
  • informed consent form (ICF) and in this protocol; OR If participant is \<18
  • parent(s) or legally authorized representative(s) (LAR) must be capable of
  • giving signed

Exclusion Criteria

  • E 01\. Chronic illness, except for LOPD, IOPD, or directly resulting from Pompe
  • disease, that, at
  • the discretion of the Investigator, could have an impact on Hex4 and
  • inflammatory markers in the CSF.
  • E 02\. Any acute illness that, at the discretion of the Investigator, could have
  • an impact on Hex4
  • and inflammatory markers in the CSF.
  • E 03\. High risk of complications from lumbar puncture or potentially associated
  • sedation, as judged by the Investigator.
  • E 04\. Concurrent treatment with any experimental drug or experimental vaccine.

Outcomes

Primary Outcomes

Not specified

Similar Trials